The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy.
Details
State: Public
Version: Final published version
Serval ID
serval:BIB_673AC528840D
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy.
Journal
Current Opinion in Pharmacology
ISSN
1471-4973 (Electronic)
ISSN-L
1471-4892
Publication state
Published
Issued date
2012
Volume
12
Number
4
Pages
478-485
Language
english
Abstract
The regulation of the immune system is controlled by many cell surface receptors. A prominent representative is the 'molecular switch' HVEM (herpes virus entry mediator) that can activate either proinflammatory or inhibitory signaling pathways. HVEM ligands belong to two distinct families: the TNF-related cytokines LIGHT and lymphotoxin-α, and the Ig-related membrane proteins BTLA and CD160. HVEM and its ligands have been involved in the pathogenesis of various autoimmune and inflammatory diseases, but recent reports indicate that this network may also be involved in tumor progression and resistance to immune response. Here we summarize the recent advances made regarding the knowledge on HVEM and its ligands in cancer cells, and their potential roles in tumor progression and escape to immune responses. Blockade or enhancement of these pathways may help improving cancer therapy.
Keywords
Animals, Antigens, CD/immunology, GPI-Linked Proteins/immunology, Humans, Neoplasms/drug therapy, Neoplasms/immunology, Receptors, Immunologic/immunology, Receptors, Tumor Necrosis Factor, Member 14/immunology, Tumor Necrosis Factor Ligand Superfamily Member 14/immunology
Pubmed
Web of science
Open Access
Yes
Create date
22/11/2012 14:26
Last modification date
20/08/2019 14:22
Usage data
